Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

Blood

Volumn 99, Issue 11, 2002, Pages 4222-4224

  Estey, Elihu H ^a,b   Giles, Francis J ^a   Beran, Miloslav ^a   O'Brien, Susan ^a   Pierce, Sherry A ^a   Faderl, Stefan H ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMTUZUMAB OZOGAMICIN; IDARUBICIN; RETINOIC ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REMISSION; TREATMENT OUTCOME;

EID: 0036625070     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0174     Document Type: Article

References (8)

1. Jurcic JG, DeBlasio T, Dumont L, Yao T-J, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM 195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372-380.
2. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol. 1999;36(4 suppl 6):2-8.
3. Sanz MA, LoCoco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
4. Estey E, Giles F, Kantarjian H, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:2230-2235.
5. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly-diagnosed acute promyelocytic leukemia without cytosine arabinoside. J Clin Oncol. 1997;15:483-490.
6. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L. All-trans retinoic acid for patients with acute promyelocytic leukemia. Leukemia. 1992;6(suppl 1):64-66.
7. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML-RARα positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
8. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP, Miller WH. Prognostic significance of minimal residual disease detection and PML/RAR α isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood. 2001;98:2651-2656.